Associated Papers
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
TPM3-NTRK1 fusion confers resistance to osimertinib in lung adenocarcinoma: a model in a continuous cell line.
Cao F et al.
Human Cell, 2025
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2025
40867048 (PubMed )
Supplement: gkaf812_supplemental_files.zip › Supplementary_Table_S5_List_of_mutations_cancer_samples.xlsx › cancer_drivers
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
40437208 (PubMed )
Supplement: 43856_2025_921_MOESM4_ESM.xlsx › Blad1
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M et al.
Translational Lung Cancer Research, 2025
40386732 (PubMed )
Supplement: tlcr-14-04-1254-supplementary.pdf
Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Lin CW et al.
Oncology Letters, 2025
39807107 (PubMed )
Supplement: Supplementary_Data2.pdf
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
39063150 (PubMed )
Supplement: ijms-25-07908-s001.zip › ijms-3103240-supplementary.pdf
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Akkhasutthikun P et al.
Cancer Research and Treatment, 2024
37986562 (PubMed )
Supplement: crt-2023-1108-Supplementary-Table-S10.pdf
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A et al.
Cancer Medicine, 2024
38457233 (PubMed )
Supplement: CAM4-13-e7077-s003.xlsx › Table_S5
Evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer.
Xu Y et al.
Journal of Thoracic Disease, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM5_ESM.xlsx › combie_list
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer.
Park IH et al.
Cancer Research and Treatment, 2024
37340844 (PubMed )
Supplement: crt-2023-408_S1_Table.pdf
Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
Fernandez SV et al.
International Journal of Molecular Sciences, 2023
Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR.
Léonce C et al.
International Journal of Molecular Sciences, 2023
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV et al.
International Journal of Molecular Sciences, 2023
37686200 (PubMed )
Supplement: ijms-24-13390-s001.zip › ijms-2558089-supplementary.pdf
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M et al.
International Journal of Molecular Sciences, 2023
37047382 (PubMed )
Supplement: ijms-24-06410-s001.zip › ijms-2177723-supplementary.pdf
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.
Serna-Blasco R et al.
Cancers, 2022
36139605 (PubMed )
Supplement: cancers-14-04446-s001.zip › Supplemental_data_S2.xlsx › dPCR_assays
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
36128861 (PubMed )
Supplement: jptm-2022-06-11-suppl1.pdf
The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors.
Lee H et al.
Cancers, 2022
35740676 (PubMed )
Supplement: cancers-14-03011-s001.zip › cancers-1735308-supplementary.pdf
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D et al.
Genes, 2022
35627184 (PubMed )
Supplement: genes-13-00799-s001.zip › genes-1613678-supplementary.pdf
PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J et al.
Frontiers in Medicine, 2022
35308511 (PubMed )
Supplement: Table_1.XLSX › Sheet1
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.
Ntzifa A et al.
Cancers, 2021
34073111 (PubMed )
Supplement: cancers-13-02736-s001.zip › cancers-1192044-supplementary.pdf
Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.
Garcia J et al.
Scientific Reports, 2021
34031447 (PubMed )
Supplement: 41598_2021_89592_MOESM1_ESM.xlsx › Supplementary_Table_S2
Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
Gilson P et al.
Scientific Reports, 2021
34006948 (PubMed )
Supplement: 41598_2021_90091_MOESM2_ESM.pdf
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z et al.
Cancer Medicine, 2021
33932095 (PubMed )
Supplement: CAM4-10-3323-s001.docx
Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.
Garcia J et al.
Molecular Diagnosis & Therapy, 2021
33660188 (PubMed )
Supplement: 40291_2021_515_MOESM1_ESM.pdf
Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.
Zhang S et al.
Frontiers in Oncology, 2021
34221970 (PubMed )
Supplement: Table_5.xlsx › Supplementary_Table_S5
The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J et al.
Frontiers in Oncology, 2021
35273907 (PubMed )
Supplement: Table_8.xlsx › Sheet1
Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
Song X et al.
British Journal of Cancer, 2020
32782293 (PubMed )
Supplement: 41416_2020_1024_MOESM1_ESM.pdf
Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate.
Arcila ME et al.
Jto Clinical and Research Reports, 2020
33511359 (PubMed )
Supplement: mmc1.docx
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S et al.
Expert Review of Molecular Diagnostics, 2020
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R et al.
Plos One, 2020
32976510 (PubMed )
Supplement: pone.0237802.s009.zip › Table_10_Accuracy_Short_Variant_Line_Data_CDx.xlsx › sheet_1
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.
Evrard SM et al.
The Journal of Molecular Diagnostics : Jmd, 2019
Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients.
Castellanos-Rizaldos E et al.
Oncotarget, 2019
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L et al.
Theranostics, 2019
31534501 (PubMed )
Supplement: thnov09p5532s1.pdf
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
30064409 (PubMed )
Supplement: 12894_2018_380_MOESM1_ESM.xlsx › Supplementary_Table_1
Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.
Decraene C et al.
Clinical Chemistry, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
29161613 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
1–50 of 75 papers
Select a paper to view details